These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 16977635)

  • 21. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
    Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
    Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expansion of gammadelta T-cells in Behçet's disease: role of disease activity and microbial flora in oral ulcers.
    Bank I; Duvdevani M; Livneh A
    J Lab Clin Med; 2003 Jan; 141(1):33-40. PubMed ID: 12518166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion of cytotoxic effectors with lytic activity against autologous blasts from acute myeloid leukaemia patients in complete haematological remission.
    Torelli GF; Guarini A; Palmieri G; Breccia M; Vitale A; Santoni A; Foa R
    Br J Haematol; 2002 Feb; 116(2):299-307. PubMed ID: 11841430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics and apoptotic profile of circulating endothelial cells as prognostic factors for induction treatment failure in newly diagnosed acute myeloid leukemia patients.
    Wierzbowska A; Robak T; Krawczyńska A; Pluta A; Wrzesień-Kuś A; Cebula B; Robak E; Smolewski P
    Ann Hematol; 2008 Feb; 87(2):97-106. PubMed ID: 17849117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T cells expressing the gammadelta receptor are essential for Th2-mediated inflammation in patients with acute exacerbation of asthma.
    Hamzaoui A; Kahan A; Ayed K; Hamzaoui K
    Mediators Inflamm; 2002 Apr; 11(2):113-9. PubMed ID: 12061423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating endothelial cells in patients with acute myeloid leukemia.
    Wierzbowska A; Robak T; Krawczyńska A; Wrzesień-Kuś A; Pluta A; Cebula B; Smolewski P
    Eur J Haematol; 2005 Dec; 75(6):492-7. PubMed ID: 16313261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics of T-cell immunity in patients with acute leukemia].
    Parovichnikova EN; Gal'tseva IV; Vorob'ev IA; Savchenko VG
    Ter Arkh; 2006; 78(7):18-25. PubMed ID: 16944746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse.
    Al-Mawali A; Gillis D; Lewis I
    Cytometry B Clin Cytom; 2009 Mar; 76(2):91-101. PubMed ID: 18727068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative real-time RT-PCR detects elevated Wilms tumor gene (WT1) expression in autologous blood stem cell preparations (PBSCs) from acute myeloid leukemia (AML) patients indicating contamination with leukemic blasts.
    Siehl JM; Thiel E; Leben R; Reinwald M; Knauf W; Menssen HD
    Bone Marrow Transplant; 2002 Mar; 29(5):379-81. PubMed ID: 11919726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse.
    Sperr WR; Mitterbauer M; Mitterbauer G; Kundi M; Jäger U; Lechner K; Valent P
    Clin Cancer Res; 2005 Sep; 11(18):6536-43. PubMed ID: 16166430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA].
    Ge W; You SG; Wang YF; Li CH; Liu XF; He XP; Ma S; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):461-4. PubMed ID: 16383235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia.
    Panoskaltsis N; Reid CD; Knight SC
    Leukemia; 2003 Apr; 17(4):716-30. PubMed ID: 12682629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Remission induction chemotherapy induces in vivo caspase-dependent apoptosis in bone marrow acute myeloid leukemia blast cells and spares lymphocytes.
    Vial JP; Tabrizi R; Pigneux A; Lacombe F; Praloran V; Belloc F
    Cytometry B Clin Cytom; 2006 May; 70(3):115-23. PubMed ID: 16572429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alphabeta T-cell receptor engineered gammadelta T cells mediate effective antileukemic reactivity.
    van der Veken LT; Hagedoorn RS; van Loenen MM; Willemze R; Falkenburg JH; Heemskerk MH
    Cancer Res; 2006 Mar; 66(6):3331-7. PubMed ID: 16540688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
    Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
    Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers.
    Adriaansen HJ; Jacobs BC; Kappers-Klunne MC; Hählen K; Hooijkaas H; van Dongen JJ
    Leukemia; 1993 Mar; 7(3):472-81. PubMed ID: 7680403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flow cytometric quantitation of natural killer cells and T lymphocytes expressing T-cell receptors alpha/beta and gamma/delta is not helpful in distinguishing benign from malignant body cavity effusions.
    Cornfield DB; Gheith SM
    Cytometry B Clin Cytom; 2009 May; 76(3):213-7. PubMed ID: 18803280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia.
    Zeleznikova T; Stevulova L; Kovarikova A; Babusikova O
    Neoplasma; 2007; 54(6):471-7. PubMed ID: 17949229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.